Key Takeaway: Jazz Pharmaceuticals will participate in Citi's 2025 Global Healthcare Conference with a fireside chat scheduled for December 2, 2025. The event will be accessible via an audio webcast, which will be archived for 30 days. This participation underscores Jazz's commitment to engaging with investors and promoting its innovative therapies.
Price reaction · baseline $180.52 (2025-11-18 close) · hit after-hours · clean, no other JAZZ news in the window
day 0 close · peak
-2.5%
Market Sentiment Analysis
POSITIVE FACTORS
Jazz Pharmaceuticals is actively engaging with investors at a major healthcare conference.
The company showcases its commitment to innovation and patient care.
The participation in the conference highlights Jazz's strategic communication efforts.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+46%
120-day peak, hindsight
Typical move
2.1%
average across 9 past catalysts
Lead asset
GWP42004
Phase 2 · Diabetes Mellitus, Type 2
Full Press Release Details
DUBLIN,Nov. 18, 2025/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq:JAZZ) today announced that the Company will participate in Citi's 2025 Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, December 2, 2025, at 6:45 a.m. PST / 9:45 a.m. EST / 2:45 p.m. GMT.
An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website athttps://investor.jazzpharma.com/investors/events-presentations. A replay of the webcast will be archived on the website for 30 days.
About Jazz PharmaceuticalsJazz Pharmaceuticals plc (Nasdaq:JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visitwww.jazzpharmaceuticals.comfor more information.